French National Database of Rare Dermatological Cancers

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity Hospital, Lille

About this trial

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes.

CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are :

* to provide epidemiological, clinical and socio-economic characteristics of patients * to identify new clinical or epidemiological prognostic factors for these rare cancers * to evaluate the impact of various treatments on outcomes

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Disqualifiers

Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Patients refusal

Trial population

Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

9,000 Participants
are grouped into 3 trial groups
Group A: Merkel cell carcinoma
Group B: Advanced basal cell carcinoma
Group C: Cutaneous adnexal carcinomas

Trial outcomes

Primary outcomes

1

Incidence and natural history of the 3 types of rare skin cancers

Time frame
10 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.